APG-1252 in Patients With SCLC or Advanced Solid Tumors
Status:
Terminated
Trial end date:
2021-04-15
Target enrollment:
Participant gender:
Summary
APG-1252 is a highly potent Bcl-2 family protein inhibitor, a promising drug candidate which
shown high binding affinities to Bcl-2, Bcl-xL and Bcl-w. The preclinical studies have shown
that APG-1252 alone achieves complete and persistent tumor regression in multiple tumor
xenograft models with a twice weekly or weekly dose-schedule, including SCLC, colon, breast
and ALL cancer xenografts; achieves strong synergy with the chemotherapeutic agents,
indicating that APG-1252 may have a broad therapeutic potential for the treatment of human
cancer as a single agent and in combination with other classes of anticancer drugs. APG-1252
is intended for the treatment of patients with SCLC or other solid tumors. Upon completion of
the Phase 1 dose escalation study to establish the maximum tolerated dose (MTD),
dose-limiting toxicities (DLTs), and/or recommended phase 2 dose (RP2D), several phase Ib/II
studies will be implemented accordingly.